Open AccessComparison of the effects of rutaecarpine on molecular subtypes of breast cancer
Author(s) -
Erdem Çokluk,
Zeynep Özman,
Gamze Güney Eskiler,
Asuman Deveci Özkan,
Mehmet Ramazan Şekeroğlu
Publication year - 2021
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_1182_20
Subject(s) - rutaecarpine , mcf 7 , breast cancer , apoptosis , pharmacology , cancer cell , annexin , cancer research , cancer , medicine , chemistry , oncology , biochemistry , human breast
Natural compounds have gained considerable attention in recent years due to disadvantages and properties of current chemotherapy drugs in cancer therapy. In addition, the impact of these compounds is specific for each type and/or subtypes of cancer due to different treatment response. Rutaecarpine, an alkaloid obtained from Evodia Rutaecarpa Chinese herb, has anticancer activity by inhibiting topoisomerase and/or cyclo-oxygenase-2 levels. However, the effectiveness of rutaecarpine has not been well known in breast cancer in terms of subtype. Therefore, we investigated the potential therapeutic effects of rutaecarpine on two different subtypes of breast cancer cells.